Palindromic Peptide LfcinB (21-25)Pal Exhibited Antifungal Activity against Multidrug-Resistant Candida

Yerly Vargas-Casanova; Jean Carlos Villamil Poveda; Zuly Jenny Rivera-Monroy; Andrés Ceballos Garzón; Ricardo Fierro-Medina; Patrice Le Pape; Javier Eduardo García-Castañeda; Claudia Marcela Parra Giraldo

doi:10.1002/slct.202001329

Palindromic Peptide LfcinB (21-25)_Pal Exhibited Antifungal Activity against Multidrug-Resistant Candida

Yerly Vargas-Casanova
, Jean Carlos Villamil Poveda
, Zuly Jenny Rivera-Monroy
, Andrés Ceballos Garzón
, Ricardo Fierro-Medina
, Patrice Le Pape
, Javier Eduardo García-Castañeda
, Claudia Marcela Parra Giraldo

Producción científica: Contribución a revista › Artículo de Investigación › revisión exhaustiva

17 Citas (Scopus)

Resumen

Palindromic peptide LfcinB (21–25)_Pal: RWQWRWQWR was synthesized by Solid Phase Peptide Synthesis (SPPS-Fmoc/tBu), purified by Reverse Phase Solid Phase Extraction (RP-SPE) and characterized by Reverse Phase High Performance Liquid Chromatography (RP-HPLC) and Matrix-Assisted Laser Desorption/Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS). The antifungal activity of LfcinB (21–25)_Pal against both ATCC strains and clinical isolates of C. albicans, C. glabrata, C. krusei, C. auris and C. tropicalis was evaluated. The palindromic peptide exhibited fungistatic and fungicidal activity against all yeast evaluated. The antifungal activity was dependent on peptide concentration in all cases. Additionally, LfcinB (21–25)_Pal (25–50 μg/mL) combined with fluconazole exhibited a synergistic antifungal effect against C. tropicalis 883 and C. krusei 6258 (resistant to fluconazole). This study showed that the palindromic peptide derived from Lactoferricin B (LfcinB) exhibited significant antifungal activity against Candida spp, suggesting that this peptide could have a therapeutic application solely or in combination with fluconazole.

Idioma original	Inglés estadounidense
Páginas (desde-hasta)	7236-7242
Número de páginas	7
Publicación	ChemistrySelect
Volumen	5
N.º	24
DOI	https://doi.org/10.1002/slct.202001329
Estado	Publicada - jun. 30 2020
Publicado de forma externa	Sí

Áreas temáticas de ASJC Scopus

Química General

Acceder al documento

10.1002/slct.202001329

Otros archivos y enlaces

Citar esto

Vargas-Casanova, Y., Carlos Villamil Poveda, J., Jenny Rivera-Monroy, Z., Ceballos Garzón, A., Fierro-Medina, R., Le Pape, P., Eduardo García-Castañeda, J., & Marcela Parra Giraldo, C. (2020). Palindromic Peptide LfcinB (21-25)_Pal Exhibited Antifungal Activity against Multidrug-Resistant Candida. ChemistrySelect, 5(24), 7236-7242. https://doi.org/10.1002/slct.202001329

@article{a12abc2fbcdf444db380607bc1dbbac8,

title = "Palindromic Peptide LfcinB (21-25)Pal Exhibited Antifungal Activity against Multidrug-Resistant Candida",

abstract = "Palindromic peptide LfcinB (21–25)Pal: RWQWRWQWR was synthesized by Solid Phase Peptide Synthesis (SPPS-Fmoc/tBu), purified by Reverse Phase Solid Phase Extraction (RP-SPE) and characterized by Reverse Phase High Performance Liquid Chromatography (RP-HPLC) and Matrix-Assisted Laser Desorption/Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS). The antifungal activity of LfcinB (21–25)Pal against both ATCC strains and clinical isolates of C. albicans, C. glabrata, C. krusei, C. auris and C. tropicalis was evaluated. The palindromic peptide exhibited fungistatic and fungicidal activity against all yeast evaluated. The antifungal activity was dependent on peptide concentration in all cases. Additionally, LfcinB (21–25)Pal (25–50 μg/mL) combined with fluconazole exhibited a synergistic antifungal effect against C. tropicalis 883 and C. krusei 6258 (resistant to fluconazole). This study showed that the palindromic peptide derived from Lactoferricin B (LfcinB) exhibited significant antifungal activity against Candida spp, suggesting that this peptide could have a therapeutic application solely or in combination with fluconazole.",

author = "Yerly Vargas-Casanova and \{Carlos Villamil Poveda\}, Jean and \{Jenny Rivera-Monroy\}, Zuly and \{Ceballos Garz{\'o}n\}, Andr{\'e}s and Ricardo Fierro-Medina and \{Le Pape\}, Patrice and \{Eduardo Garc{\'i}a-Casta{\~n}eda\}, Javier and \{Marcela Parra Giraldo\}, Claudia",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley-VCH Verlag GmbH \& Co. KGaA, Weinheim",

year = "2020",

month = jun,

day = "30",

doi = "10.1002/slct.202001329",

language = "English (US)",

volume = "5",

pages = "7236--7242",

journal = "ChemistrySelect",

issn = "2365-6549",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "24",

}

Vargas-Casanova, Y, Carlos Villamil Poveda, J, Jenny Rivera-Monroy, Z, Ceballos Garzón, A, Fierro-Medina, R, Le Pape, P, Eduardo García-Castañeda, J & Marcela Parra Giraldo, C 2020, 'Palindromic Peptide LfcinB (21-25)_Pal Exhibited Antifungal Activity against Multidrug-Resistant Candida', ChemistrySelect, vol. 5, n.º 24, pp. 7236-7242. https://doi.org/10.1002/slct.202001329

TY - JOUR

T1 - Palindromic Peptide LfcinB (21-25)Pal Exhibited Antifungal Activity against Multidrug-Resistant Candida

AU - Vargas-Casanova, Yerly

AU - Carlos Villamil Poveda, Jean

AU - Jenny Rivera-Monroy, Zuly

AU - Ceballos Garzón, Andrés

AU - Fierro-Medina, Ricardo

AU - Le Pape, Patrice

AU - Eduardo García-Castañeda, Javier

AU - Marcela Parra Giraldo, Claudia

PY - 2020/6/30

Y1 - 2020/6/30

N2 - Palindromic peptide LfcinB (21–25)Pal: RWQWRWQWR was synthesized by Solid Phase Peptide Synthesis (SPPS-Fmoc/tBu), purified by Reverse Phase Solid Phase Extraction (RP-SPE) and characterized by Reverse Phase High Performance Liquid Chromatography (RP-HPLC) and Matrix-Assisted Laser Desorption/Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS). The antifungal activity of LfcinB (21–25)Pal against both ATCC strains and clinical isolates of C. albicans, C. glabrata, C. krusei, C. auris and C. tropicalis was evaluated. The palindromic peptide exhibited fungistatic and fungicidal activity against all yeast evaluated. The antifungal activity was dependent on peptide concentration in all cases. Additionally, LfcinB (21–25)Pal (25–50 μg/mL) combined with fluconazole exhibited a synergistic antifungal effect against C. tropicalis 883 and C. krusei 6258 (resistant to fluconazole). This study showed that the palindromic peptide derived from Lactoferricin B (LfcinB) exhibited significant antifungal activity against Candida spp, suggesting that this peptide could have a therapeutic application solely or in combination with fluconazole.

AB - Palindromic peptide LfcinB (21–25)Pal: RWQWRWQWR was synthesized by Solid Phase Peptide Synthesis (SPPS-Fmoc/tBu), purified by Reverse Phase Solid Phase Extraction (RP-SPE) and characterized by Reverse Phase High Performance Liquid Chromatography (RP-HPLC) and Matrix-Assisted Laser Desorption/Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS). The antifungal activity of LfcinB (21–25)Pal against both ATCC strains and clinical isolates of C. albicans, C. glabrata, C. krusei, C. auris and C. tropicalis was evaluated. The palindromic peptide exhibited fungistatic and fungicidal activity against all yeast evaluated. The antifungal activity was dependent on peptide concentration in all cases. Additionally, LfcinB (21–25)Pal (25–50 μg/mL) combined with fluconazole exhibited a synergistic antifungal effect against C. tropicalis 883 and C. krusei 6258 (resistant to fluconazole). This study showed that the palindromic peptide derived from Lactoferricin B (LfcinB) exhibited significant antifungal activity against Candida spp, suggesting that this peptide could have a therapeutic application solely or in combination with fluconazole.

UR - https://www.scopus.com/pages/publications/85087119114

UR - https://www.scopus.com/pages/publications/85087119114#tab=citedBy

U2 - 10.1002/slct.202001329

DO - 10.1002/slct.202001329

M3 - Research Article

AN - SCOPUS:85087119114

SN - 2365-6549

VL - 5

SP - 7236

EP - 7242

JO - ChemistrySelect

JF - ChemistrySelect

IS - 24

ER -